Mr. Dhillon is the co-founder, Director, President, and CEO of OncoSec Medical. Formerly the VP of finance and operations at Inovio Pharmaceuticals, Inc., Mr. Dhillon raised in excess of $125 million through multiple financings and several licensing deals. He was also instrumental to the successful in-licensing of key intellectual property and a number of corporate transactions, including the acquisition and consolidation of Inovio AS, a Norwegian DNA delivery company, and the merger with VGX Pharmaceuticals.
Mr. Dhillon has also been a consultant and board member for several early stage life science companies.
Mr. Lytle is a pharmaceutical and biotechnology executive with a demonstrated track record spanning more than 35 years of progressive experience in commercializing products in multiple markets and therapeutic categories at market-leading companies.
He began his extensive career in the healthcare industry at Pfizer in 1971. In over 20 years with the company, he gained a broad range of industry and commercial experience in a series of sales, marketing, and management positions including Group Product Manager, Antibiotics, and Vice President, Marketing. He was part of the team working to develop Sulbactam™, a first-generation b-Lactamase Inhibitor.
Tom joined Amgen in 1997 and led efforts to build new capabilities in market research, corporate accounts, and competitive analysis. . He was appointed Vice President, New Products in 1999 where his responsibilities included shaping of markets and products for launch and developing plans for the commercialization of new products. In 2002 he became Vice President, Strategic Marketing and Business Development and led efforts to bring innovative and forward-looking business solutions to customer and market problems.
In January 2006 Tom launched Strategic Choices, LLC, a well-networked healthcare consulting practice focused on helping a select group of small and emerging companies build core strategies, develop options, and make the hard choices necessary to achieve key objectives.
In December 2006 Tom was elected to the Board of Directors of Neogenix Oncology, Inc., a clinical stage oncology therapeutics and diagnostic company focusing on pancreatic and other cancers, where he also served as Chief Operating and Administrative Officer. In late 2011, he licensed a portfolio of products from the Penn State Research Foundation and founded Melanovus Oncology, an early-stage biotechnology company developing first-in-class therapeutics for the treatment of melanoma and skin cancers. As CEO, he successfully negotiated the exit of the firm to Cipher Pharmaceuticals in December of 2014.
Tom is an Adjunct Professor at the University of the Sciences in Philadelphia, teaching graduate level courses in Pharmaceutical Sales and Marketing Competitive Analysis and Business Strategy. He earned his Bachelor’s degree in marketing at Western Michigan University in 1968 and his MBA at LaSalle University in Philadelphia in 1981. In 1993 Tom retired from the US Army Reserve as a Colonel after 25 years of active and reserve service.
Ms. Keller has more than 30 years of experience in clinical development and clinical trial execution. Starting in academic clinical research at the Cancer Research Institute, UC Davis and San Francisco, she subsequently held positions of increasing responsibility in large and small pharma, biotech, diagnostics, and CRO companies.
She has worked with Agouron as a Senior Director and Head of Clinical Operations, New Drug Services as Director of Clinical Operations and Client Services; Pfizer as an Executive Director with operational clinical development responsibilities; Shire Pharmaceuticals as Vice President of Global Clinical Development; Prometheus Laboratories as Vice President Clinical Development and Operations; and Sangart as Vice President of Clinical Operations.
Her experience ranges from small molecule and biologics to molecular diagnostics.
She graduated from UC Davis and completed an Executive Leadership program at Wharton.
She is the Regional Director at Large for the SoCal Chapter of the Healthcare Business Women’s Association (HBA), a member of the advisory board for IIR Partnerships in Clinical Trials, a member of the editorial board of Life Science Leader magazine, and a frequent conference speaker. Mary Rose is currently working as an executive consultant in clinical research, development, and operations.
Mr. Vennare is an accomplished senior executive and biotech entrepreneur with more than two decades experience building, launching and growing companies across diverse markets in the life sciences, biotechnology and information technology sectors.
Raymond’s expertise as a founder, investor, board director and business advisor encompasses critical areas of executive leadership including corporate governance, business development, strategic planning, stakeholder relations and capital formation.
Raymond is currently the Founder and Principal of a business practice serving clients as diverse as nationally ranked universities and philanthropic foundations to multi-national publicly traded companies. In the past, Raymond has served as Co-founder and CEO of Thermal Therapeutic Systems; President and Chief Executive Officer of ImmunoSite; Senior Vice President and Chief Information Officer of TissueInformatics; Partner and President of VS/Interactive and Founder; and President of the Fine Art Inventory Network.
Raymond is a graduate of the University of Pittsburgh (BA), Case Western Reserve University (MA), and Duquesne University (MS). Continuing Education includes: Carnegie Mellon University, Donald H. Jones Center for Entrepreneurship (Certificate, Technology Commercialization) and, Massachusetts Institute of Technology, Sloan School of Business (Managing Corporate Innovation).
Dr. Lane is a board certified physician, attorney, business leader and public health advocate functioning at the critical interface of clinical medicine, business and law to deliver organizational performance.
In 2009 he founded Vector Healthcare Solutions, a consultancy focused on the implementation of paperless medical environments using proprietary online customized systems to assist medical institutions in achieving mandated and desired changes required to generate and document value-based care for reimbursement. In this role he provides management of patient safety using healthcare informatics, knowledge and content management, business process analysis, and organizational change management.
Philip received his Bachelor of Applied Science, MBA, and Masters of Public Health from the University of South Florida, his MD from the University of Illinois, and his JD from the Illinois Institute of Technology.
Mr. Lander is a Registered Patent Agent, whose U.S. and international patent prosecution practice focuses upon strategic patent portfolio development in the life sciences, particularly chemistry, chemical engineering, biotechnology and medical devices. Mr. Lander collaborates with a select group of corporate, securities, trademark and FDA counsel, in order to provide strategic assistance to start-‐up and early stage companies, thereby furthering their efforts to secure financing, and monetize their Intellectual Property portfolios.
Mr. Lander joined the U.S. Patent & Trademark Office in 1973 and served as a Primary Examiner in the chemical arts. During his 25-year tenure with the USPTO he was selected for a number of special projects, working with the Commissioner of Patents on the “Paperless Patent Office” project, which was the foundation of the paperless, digitized system in use today.
Mr. Lander subsequently practiced with the McHale & Slavin, P.A. law firm from 1998 until 2011, where he specialized in both U.S. and International prosecution of patent applications in the fields of biotechnology, chemistry and chemical engineering related subject matter. Particular areas of technology included pharmaceutical compositions and carriers, biotechnology processes and products produced thereby, e.g. cancer antibody technology, metabolic syndrome technologies, and blood treatment technologies. Mr. Lander has been responsible for the strategic development of several patent portfolios, which ultimately became a critical element in the successful exit strategies of his clients.
Mr. Lander received a Bachelor of Science in Chemical Engineering from the Polytechnic Institute of Brooklyn, where he was President of the Omega Chi Epsilon Chemical Engineering Honor Society, and a member of Phi Lambda Upsilon Chemical Honor Society and the Tau Beta Pi Engineering Honor Society. He is currently a member of the Patent & Trademark Office Society, the Intellectual Property Law Association of Florida, BioFlorida, the American Intellectual Property Law Association, and the National Association of Patent Practitioners. He also serves as Vice President of the Angel Investment Forum of Florida, and is an active supporter of the South Florida Life Science Technology Hub.
Mr. Mino brings an extremely unique background to Gordian. In addition to having significant experience in sales, marketing, and academic research, Mr. Mino has graduate degrees in law, business and medical science. He is currently employed by Somahlution, Inc., as the General Manager of Global Pharma Analytics, LLC, a CGMP compliant analytical chemistry laboratory in Jupiter, FL, serving drug, medical device, and nutraceuticals clients.
Mr. Mino has worked in the life sciences for almost two decades. After conducting academic molecular biology research for almost five years, he joined industry working with companies such as Sigma-Aldrich, Roche Diagnostics, and Applied Biosystems. During his career, Mr. Mino has served in various leadership capacities, such as vice president roles in sales, marketing, and licensing, as well as general counsel, among others.
Mr. Mino received his JD, MBA, and MS in Medical Sciences (Pharmacology and Genetics) from the University of Florida and his BS (Genetics) from the University of Georgia. He is a registered patent attorney with the USPTO and is a Member of the Florida Bar.
Mr. Tiberend is President and CEO of Tiberend Strategic Advisors, Inc. and has 30 years’ experience counseling senior management and has developed and executed strategic corporate communications programs for both publicly traded and private companies from emerging growth venture backed companies to those companies filing an IPO. Greg co-founded Richard Lewis Communications, Inc. (the predecessor company to Tiberend Strategic Advisors) in 1989 and spent 10 years building the business. He rejoined the firm in June 2005 and in May 2008, Greg became president & CEO.
Prior to re-joining the firm, Greg spent three years leading the healthcare practice as Executive Vice President at The Ruth Group where he built significant revenue for the life sciences group and counseled senior management on investor communications programs.
From 1999 to 2002, Greg was a Vice President at Morgen-Walke Associates, Inc. (now part of FTI Consulting) where he led multiple practice areas – healthcare and business services.
Having developed strong relationships during his career with investment bankers, venture capitalist and journalists, Greg has counseled more than 75 companies in the areas of biotechnology, specialty pharmaceutical, generic pharmaceutical, medical device, diagnostics, healthcare services and financial services. He works with clients to best convey the value proposition that will resonate with multiple audiences including investors and potential partners.
Greg is a 1984 graduate of the University of Illinois at Urbana-Champaign